A new study seems to indicate that adding cetuximab to the standard therapy for resected stage 3 colon cancer provides no additional benefits.
A large randomized multicenter study found no benefit to adding cetuximab (Erbitux) to the standard adjuvant therapy for resected stage 3 colon cancer, according to a study published in JAMA.
The randomized trial involved 2,686 patients aged 18 years or older at multiple institutions across North America with resected stage 3 wild-type KRAS colon cancer.
The adjuvant therapy used in this study is the modified sixth version of leucovorin, fluorouracil, and oxaliplatin (FOLFOX). Adding cetuximab to FOLFOX had been shown to benefit patients who have metastatic wild-type KRAS colon cancer, but not those with mutated KRAS colon cancer. Both treatment groups received mFOLFOX6, consisting of 12 biweekly courses of oxaliplatin (85 mg/m2 ) over 2 hours on day 1 with leucovorin (400 mg/m2) and fluorouracil (400 mg/m2) bolus, then 46-hour intravenous fluorouracil (2,400 mg/m2) on days 1 to 2 starting within 10 weeks of surgery. Patients enrolled in the cetuximab group received 400 mg/m2 over 2 hours on day 1 of cycle 1, then 250 mg/m2 over 1 hour on day 8 (cycle 1) and day 1 and 8 each of cycles 2 through 12.
Cetuximab is indicated for stage 4 colon cancer, cancer that has metastasized beyond the colon, according to Lisa Holle, PharmD, BCOP, assistant clinical professor, department of pharmacy practice, University of Connecticut School of Pharmacy, Farmington, Conn.
Cetuximab is a recombinant, human/mouse chimeric monoclonal antibody that is an epidermal-growth-factor receptor (EGFR) inhibitor. It is usual to test a drug that is effective against advanced cancer in patients whose cancer has not metastasized beyond the colon, Dr Holle said. Sometimes these drugs are found to be effective earlier and sometimes they aren't, she noted.
The published study was accompanied by an editorial that noted that testing drugs in refractory cases first and then in less refractory cases was a time-honored and rational approach, especially in treating colon cancer.
Why there is not benefit to using cetuximab in earlier stages of colon cancer remains to be determined, Dr Holle said.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.